GOSS - Gossamer Bio, Inc.
| Previous Close | 16.43 |
| Open | 16.57 |
| Bid | 16.09 x 800 |
| Ask | 21.97 x 800 |
| Day's Range | 15.80 - 16.84 |
| 52 Week Range | 14.63 - 25.06 |
| Volume | 374,235 |
| Avg. Volume | 454,475 |
| Market Cap | 1.063B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.95 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
- GuruFocus.com
Weekly CEO Buys Highlight
Insiders invest in Gossamer Bio, Heron Therapeutics and Athenex Continue reading...
- Business Wire
Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2 at 7:45 a.m. ET. Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
- GuruFocus.com
Seth Klarman Further Increases Translate Bio Stake
Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...
- Business Wire
Gossamer Bio Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced Otello Stampacchia, Ph.D., of Omega Funds, resigned from the company’s Board of Directors. Dr. Stampacchia has served as a director of the company since January 2018, and Omega Funds was the founding seed investor of Gossamer. “The support and resources we received from Otello and Omega were critical to launching Gossamer in January 2018,” said Faheem Hasnain, Chairman of Gossamer.
- GuruFocus.com
Baupost's Seth Klarman Dives Further Into Translate Bio
Guru adds to position in biotech company that focuses on genetic diseases Continue reading...
- Zacks
Implied Volatility Surging for Gossamer Bio (GOSS) Stock Options
Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.
- GuruFocus.com
Seth Klarman's Small Biotech Holdings
A look at some of the guru's smaller, overlooked positions Continue reading...
Motley FoolGossamer Bio, Inc. (GOSS) Q2 2019 Earnings Call Transcript
GOSS earnings call for the period ending June 30, 2019.
- Simply Wall St.
Read This Before Selling Gossamer Bio, Inc. (NASDAQ:GOSS) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
GuruFocus.comSeth Klarman's Favorite Biotech Positions
Some ideas from Baupost's pharmaceutical portfolio
GuruFocus.comSeth Klarman Introduces 7 New Positions in 1st Quarter
Baupost’s new positions include companies formed by Disney-Fox merger
Motley FoolGossamer Bio, Inc. (GOSS) Q1 2019 Earnings Call Transcript
GOSS earnings call for the period ending March 31, 2019.
- Associated Press
Gossamer Bio: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 90 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment ...
- Business Wire
Gossamer Bio Announces First Quarter 2019 Financial Results
– Multiple trial initiations and data readouts expected in the next 12 months –
- Simply Wall St.
How Much Of Gossamer Bio, Inc. (NASDAQ:GOSS) Do Insiders Own?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Business Wire
Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2019 financial results on Tuesday, May 14, 2019.
- Business Wire
Gossamer Bio Secures Debt Facility for up to $150 Million
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced it entered into a five-year senior debt facility led by MidCap Financial (MidCap). The lenders under the debt facility, including affiliates of MidCap, will make available to Gossamer an aggregate principal amount up to $150 million. The facility provides the company with access to capital for general corporate purposes and to support the development of Gossamer’s development candidates.
- Business Wire
Gossamer Bio Announces Participation in Bank of America Merrill Lynch Health Care Conference 2019
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14 at 1:00 p.m. PT. Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
- Business Wire
Gossamer Bio Announces 2018 Annual Financial Results
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments.
- Business Wire
Gossamer Bio Announces Participation in Upcoming Investor Conferences
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of
- GuruFocus.com
Gossamer Aims to Be Genentech Clone
The executive chairman of Gossamer Bio (NASDAQ: GOSS) has a lofty goal for the company: Be the next version of Genentech, the biotechnology giant that is now a subsidiary of Roche (OTCPK: RHHBY). The odds are high, but Faheem Hasnain's track record suggests he may have assembled just the team to make that dream a reality. If the company comes anywhere near being the next Genentech, the share price will prove to be the biggest bargain since the purchase of Alaska.
- Business Wire
Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to the public of $16.00 per share. Including the option exercise, the aggregate gross proceeds to Gossamer Bio from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $317.4 million. BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as joint book-running managers for the offering.
